The alterations of serum FGF-21 levels, metabolic and body composition in early breast cancer patients receiving adjuvant endocrine therapy

Akyol M., ALACACIOĞLU A., DEMİR L., KÜÇÜKZEYBEK Y., Yildiz Y., Gumus Z., ...More

CANCER BIOMARKERS, vol.18, no.4, pp.441-449, 2017 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 18 Issue: 4
  • Publication Date: 2017
  • Doi Number: 10.3233/cbm-161507
  • Journal Name: CANCER BIOMARKERS
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.441-449
  • Keywords: Breast cancer, serum FGF 21, glucose metabolism, lipid metabolism, tamoxifen, aromatase inhibitors, GROWTH-FACTOR 21, NONALCOHOLIC FATTY LIVER, AROMATASE INHIBITOR LETROZOLE, HEALTHY POSTMENOPAUSAL WOMEN, CARDIOVASCULAR-DISEASE, TAMOXIFEN TREATMENT, LIPID PROFILE, BETA-KLOTHO, OBESITY, FGF21
  • Dokuz Eylül University Affiliated: Yes

Abstract

BACKGROUND: In early breast cancer patients, the effects of hormonal therapy (tamoxifen and aromatase inhibitors) on plasma fibroblast growth factor 21 (FGF-21), lipid levels and body composition have not yet been investigated. Therefore, we aimed to analyze the relationship between FGF-21 and body composition as well as the effects of tamoxifen and aromatase inhibitors on plasma lipid levels, FGF-21, and body composition.